This analysis demonstrates gemcitabine and BRD4-degrading agent improve tumor regression in non-small cell lung cancer, suggesting enhanced therapeutic outcomes through ferroptosis.
Nonsmall cell lung cancer (NSCLC) exhibits high malignancy, low survival rates, and unfavorable prognosis. As a primary chemotherapy agent for NSCLC, gemcitabine (GEM) suppresses RNA/DNA synthesis to trigger cancer cell apoptosis. Nevertheless, GEM therapy is limited by systemic toxicity and suboptimal efficacy. Combining GEM with other small-molecule kinase inhibitors frequently enhances therapeutic outcomes. Bromodomain-containing protein 4 (BRD4), a critical epigenetic regulator implicated in transcriptional control, shows strong associations with tumor progression. This study demonstrates that BRD4 degradation via the PROTAC molecule MZ1 potentiates NSCLC susceptibility to GEM. To enable codelivery, a GSH-responsive nano prodrug, BT-GEM/MZ1@NP, was strategically engineered. Compared to GEM or MZ1 monotherapy, BT-GEM/MZ1@NP demonstrated a more potent antitumor profile fostering a synergistic therapeutic through ferroptosis induction. In vivo assessment substantiated significantly enhanced tumor regression with ferroptosis promotion. These findings nominate BT-GEM/MZ1@NP as a promising clinical candidate for NSCLC therapy.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: